BioSpace News Archive

Genentech’s Hemlibra Data Continues to Wow at ASH

One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.

December 10, 2017

·

4 min read

·

Alex Keown

Gemini Therapeutics Banks $42.5M to Bring Precisio

Drug Development

Syros Crushed as Lead Drug is Failing Its Phase II Trial Badly

Investors are not happy with interim Phase II data presented by Syros.

December 10, 2017

·

2 min read

·

Alex Keown

Drug Development

bluebird, Celgene Tout ‘Unheard of’ Early-Stage Multiple Myeloma Data

Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.

December 10, 2017

·

2 min read

·

Mark Terry

Drug Development

Bioverativ Release: Study Shows Weekly Prophylactic Treatment With ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People With Hemophilia A

The analysis is being presented today in a poster session at the 59th Annual Meeting of the American Society of Hematology.

December 10, 2017

·

10 min read

Genetown

Acceleron Announces Updated Results From Ongoing Phase II Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology

Acceleron announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

December 10, 2017

·

9 min read

Drug Development

Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With r/r DLBCL, a Difficult-to-Treat Cancer

The data from this pivotal trial, led by researchers from the University of Penn, show an ORR of 53%, 42% 64%; p<0.0001, with 40% achieving a CR and 14% achieving a PR among 81 infused patients with three or more months of follow-up or earlier discontinuation.

December 10, 2017

·

17 min read

Moffitt Cancer Center Release: New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

The new long-term results of the ZUMA-1 clinical trial reported measurable responses in 82 percent of patients and complete responses in 54 percent of patients.

December 10, 2017

·

3 min read

Drug Development

bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

bluebird bio announced data from two studies of its LentiGlobin gene therapy product candidate in patients with transfusion-dependent β-thalassemia (TDT).

December 10, 2017

·

10 min read

Dana-Farber Cancer Institute Joins the Parker Inst

Business

Janssen to Terminate Simeprevir License With Medivir, Effective June 2018

Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time.

December 10, 2017

·

1 min read

Drug Development

PharmaEssentia Announces Favorable Two-Year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ASH Annual Meeting 2017

Results reported last year at ASH 2016 showed that at 12 months, Ropeginterferon alfa-2b demonstrated non-inferiority to hydroxyurea in Complete Hematologic Response.

December 10, 2017

·

5 min read